Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors - Trial NCT01642342
Access comprehensive clinical trial information for NCT01642342 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Southern California and is currently Terminated. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 102 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Southern California
Timeline & Enrollment
Phase 1
Sep 06, 2012
May 29, 2019
Primary Outcome
Toxicities observed at each dose level utilizing the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0,Number of patients with complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or inevaluable (IE),Survival,Time to failure
Summary
This study is about an experimental drug called sEphB4-HSA (recombinant albumin fusion
 protein sEphB4-HSA). This research study will be the first time sEphB4-HSA is given to
 people. sEphB4-HSA prevents tumor cells from multiplying and blocks several compounds that
 promote the growth of blood vessels that bring nutrients to the tumor. sEphB4-HSA has shrunk
 colon, lung, breast, glioma, melanoma, prostate and Kaposi's sarcoma tumors in mice
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01642342
Non-Device Trial